These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 16154489)
1. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. Garnett WR; Gilbert TD; O'Connor P Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489 [TBL] [Abstract][Full Text] [Related]
2. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis. Jackson J; Fernandes AW; Nelson W Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318 [TBL] [Abstract][Full Text] [Related]
3. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Miller AD; Krauss GL; Hamzeh FM Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458 [TBL] [Abstract][Full Text] [Related]
4. Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients. Ginsberg LD Ann Clin Psychiatry; 2006; 18 Suppl 1():9-14. PubMed ID: 16754406 [TBL] [Abstract][Full Text] [Related]
5. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274 [TBL] [Abstract][Full Text] [Related]
6. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. Konsil J; Dechasathian S; Mason DH; Stevens RE J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869 [TBL] [Abstract][Full Text] [Related]
7. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study. El-Mallakh RS; Salem MR; Chopra AS; Mickus GJ; Penagaluri P Int Clin Psychopharmacol; 2009 May; 24(3):145-9. PubMed ID: 19367153 [TBL] [Abstract][Full Text] [Related]
8. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Rascati KL; Richards KM; Johnsrud MT; Mann TA Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250 [TBL] [Abstract][Full Text] [Related]
9. Safety of carbamazepine extended-release capsules in bipolar disorder polypharmacy. Ginsberg LD Ann Clin Psychiatry; 2006; 18 Suppl 1():19-22. PubMed ID: 16754408 [TBL] [Abstract][Full Text] [Related]
10. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data. Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622 [TBL] [Abstract][Full Text] [Related]
11. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128 [TBL] [Abstract][Full Text] [Related]
12. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Davis KL; Candrilli SD; Edin HM Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549 [TBL] [Abstract][Full Text] [Related]
15. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Powell G; Saunders M; Marson AG Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617 [TBL] [Abstract][Full Text] [Related]
16. [The clinical and economic impact of generic drugs in the treatment of epilepsy]. Argumosa A; Herranz JL Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330 [TBL] [Abstract][Full Text] [Related]
17. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Ficker DM; Privitera M; Krauss G; Kanner A; Moore JL; Glauser T Neurology; 2005 Aug; 65(4):593-5. PubMed ID: 16116122 [TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986 [TBL] [Abstract][Full Text] [Related]
19. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients. Kwong WJ; Kamat S; Fang C Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608 [TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]